Welcome to the 1st Interstitial Lung Disease Drug Development Summit

Network with over 50 other industry pioneers including Ionis Pharmaceuticals, Genentech, Vicore and AnaMar to hear first-hand how the latest scientific research is innovating and upgrading ILD therapeutics at this trailblazing new meeting.

The 1st Interstitial Lung Disease Drug Development Summit is a ground-breaking new conference dedicated to helping you drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF.

Unmissable Highlights Include

  • Scrutinize the progressive phenotype of fibrosing interstitial lung disease with Boehringer Ingelheim to deepen your understanding of the lumping versus splitting debate and confidently determine which approach you should take to optimize your clinical trial design

 

  • Carefully examine success’, challenges and failures from IPF clinical trials to understand how you can avoid making the same mistakes and accelerate success in developing ILD therapies withToby Maher

 

  • Investigate the buzz surrounding taking apreventative measures in tackling fibrosis in coronavirus patients with Gisli Jenkins and uncover how this could impact treatment strategies for other fibrosing pulmonary phenotypes in 2021 and beyond

 

  • Gain vital insights from Novartis on the pros and cons of sarcoidosis drug development to identify what factors are important to consider when creating successful sarcoidosis clinical trials

 

  • Review the full spectrum of combination trials from triple therapy to 2 anti-fibrotic combination therapy with Roche to understand how to accurately measure the efficacy of novel therapeutics as more and more drugs receive approvals in 2021 and beyond

 

  • Discover the latest cutting-edge research on ILD biomarkers with Ionis Pharmaceuticalsand analyze the emerging consensus to determine which biomarker is the most useful from an ILD drug development perspective

Join the leading experts as they unite to disseminate the crucial insights you need to confidently define, understand and develop clinically effective antifibrotic therapies against the progressive fibrosing ILD phenotype Scleroderma, Sjogren’s Syndrome, Sarcoidosis, Hypersensitivity Pneumonitis and more.